Pharma
Built for companies too small to have a commercial machine, in an industry that assumes you have one.
We launch with pharma services companies selling into biopharma. Small commercial pharma follows. The engine is the same; the rules are not.
Launching now
Pharma services selling into biopharma
CDMOs, CROs, and specialty vendors whose customers are sponsors with programs, timelines, and budgets you can see coming.
What revenue lift means here
Qualified RFP invitations, proposal win rate, and expansion inside sponsors you already serve. Bookings lag by quarters, so we track the leading indicators weekly and the bookings when they land.
What the Read looks at
The sponsors most likely to need you next quarter, from public sources: trial phase transitions, financings, approvals, hiring signals, and what your own site says and does not say about you.
What gets done
Target lists with the trigger and the angle. Follow-up sequences after site visits and audits. Proposal and pricing drafts. A credibility statement about your regulatory track record, with the source cited. Every outbound message goes out under your name with your approval.
Coming next
Small commercial pharma
One to three marketed products, a lean field team, a compliance function that reviews everything. What changes, in plain terms:
We draft. Your review process approves.
Anything that could reach a prescriber, patient, or payer is drafted with a claims-to-references matrix and handed to your medical, legal, and regulatory review. We never publish it. Not ever.
We read your data under your agreements.
If you license prescription or claims data, we read exports or a read-only connection under your license terms. We do not license patient or prescriber data ourselves, and we never ingest patient-level records.
What we will not propose.
No transfers of value to healthcare professionals. No off-label implication. No direct-to-consumer content in the first 90 days of any engagement. Every regulatory-status claim cites a source.
PlaceholderWhich pharma segment launches first is being confirmed with our pharma subject-matter expert. The service design above is our current plan, not a promise.
Why a services company would let us look
Because the first thing we do costs you nothing and asks for nothing. The Read is built from public information and ten answers. If it is not specific about your sponsors, you will know in the first paragraph.
See what we would notice about your company.
Ten questions. Public data. A Read signed by a partner, within hours. If it is useful, we keep going. If not, you keep the Read.